Author: admin

DelveInsight’s “22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the 22q11.2 Deletion Syndrome Market Report:

https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

Some of the key facts of the 22q11.2 Deletion Syndrome Market Report:

• The 22q11.2 Deletion Syndrome market size was valued at nearly USD 14 million in 2025 and is anticipated to register a CAGR of 32% during the forecast period from 2026 to 2036.

• In April 2025, ZYN002 is the first pharmaceutically produced synthetic cannabidiol formulated as a patented permeation-enhanced gel for transdermal absorption directly through the skin into the bloodstream—completely free of THC. Unlike cannabis-derived products, ZYN002 is synthetically manufactured in a cGMP-certified facility and does not cause the psychoactive effects associated with THC. If approved, it may qualify as a nonscheduled medication. The active compound, cannabidiol, has been granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) for Fragile X Syndrome (FXS) and 22q11.2 deletion syndrome (22q). Moreover, ZYN002 has also received FDA Fast Track designation for addressing behavioral symptoms in FXS.

• Among the 7MM, the US accounted for the largest market size of 22q11.2 Deletion Syndrome. i.e., ~USD 8 million in 2025.

• In EU4 and the UK, Germany and the UK captured the largest share of 22q11.2 deletion syndrome market, while Spain accounted for the least share.

• The entry of NB-001 is expected capture a significant share in the 22q11.2 Deletion Syndrome landscape.

• It is a lifelong condition and the most common chromosomal microdeletion syndrome, significantly impacting development, cognition, and behavioral health, with an estimated prevalence of ~1 in 4,000 live births.

• A substantial proportion of patients experience neurocognitive impairment and psychiatric disorders, including a markedly elevated risk of schizophrenia (~25% in adults), making 22q11.2DS one of the strongest known genetic risk factors for severe mental illness.

• According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of 22q11.2 deletion syndrome in the 7MM was ~ 101,500.

• In the United States, among age-specific diagnosed prevalent cases of 22q11.2 deletion syndrome, infant accounted for the majority of cases (~12,550), followed by 1 ̶ 5 years (~10,300), 6 ̶ 12 years (~19,550), 18+ years (~7,000), and 13 ̶ 17 years (~4,800) in 2025.

• Among EU4 and the UK Germany accounted for the highest number of diagnosed prevalent cases of 22q11.2 Deletion Syndrome (~9,300 cases), while Spain reported the lowest burden (~6,100 cases) in 2025, highlighting regional variability in diagnosis and disease recognition.

• In Japan, the diagnosed prevalent cases of 22q11.2 deletion syndrome with behavioral and psychiatric phenotypes were approximately 7,650 in 2025.

• Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others

• Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others

• The 22q11.2 Deletion Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage 22q11.2 Deletion Syndrome pipeline products will significantly revolutionize the 22q11.2 Deletion Syndrome market dynamics.

22q11.2 Deletion Syndrome Overview

22q11.2 Deletion Syndrome, also known as DiGeorge Syndrome or Velocardiofacial Syndrome, is a genetic disorder caused by the deletion of a small segment of chromosome 22. It can lead to a wide range of symptoms, including heart defects, immune system problems, developmental delays, speech and language difficulties, and learning challenges. Individuals with this syndrome may also have distinct facial features and may be at a higher risk for psychiatric conditions. The severity and range of symptoms can vary greatly, and treatment focuses on addressing specific health concerns and providing supportive care.

To Know in detail about the 22q11.2 Deletion Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; 22q11.2 Deletion Syndrome Market Forecast

22q11.2 Deletion Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

22q11.2 Deletion Syndrome Epidemiology Segmentation:

The 22q11.2 Deletion Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of 22q11.2 Deletion Syndrome

• Prevalent Cases of 22q11.2 Deletion Syndrome by severity

• Gender-specific Prevalence of 22q11.2 Deletion Syndrome

• Diagnosed Cases of Episodic and Chronic 22q11.2 Deletion Syndrome

Download the report to understand which factors are driving 22q11.2 Deletion Syndrome epidemiology trends @ 22q11.2 Deletion Syndrome Epidemiology Forecast

22q11.2 Deletion Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the 22q11.2 Deletion Syndrome market or expected to get launched during the study period. The analysis covers 22q11.2 Deletion Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the 22q11.2 Deletion Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

22q11.2 Deletion Syndrome Therapies and Key Companies

• RETHYMIC (formerly RVT-802): Sumitomo Pharma/Enzyvant/Roivant Sciences

• NB-001: Nobias Therapeutics

• ZYN002: Zynerba Pharmaceuticals, Inc.

• NB-001: Nobias Therapeutics, Inc.

• Metyrosine: Bausch Health Americas, Inc.

Discover more about therapies set to grab major 22q11.2 Deletion Syndrome market share @ 22q11.2 Deletion Syndrome Treatment Market

22q11.2 Deletion Syndrome Market Drivers

• 22q11.2 deletion syndrome is a rare genetic condition; thus, companies developing treatment options for the same can possess several advantages like 7-year market exclusivity, orphan drug designation, and others.

22q11.2 Deletion Syndrome Market Barriers

• There exists no approved treatment for the syndrome, as a result, there are several chances for the companies to investigate unmet requirements and develop therapeutic choices that will benefit the patient population and leverage this prevalent orphan indication.

Scope of the 22q11.2 Deletion Syndrome Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key 22q11.2 Deletion Syndrome Companies: Zynerba Pharmaceuticals, Inc., Nobias Therapeutics, Inc., Bausch Health Americas, Inc., and others

• Key 22q11.2 Deletion Syndrome Therapies: ZYN002, NB-001, Metyrosine, and others

• 22q11.2 Deletion Syndrome Therapeutic Assessment: 22q11.2 Deletion Syndrome current marketed and 22q11.2 Deletion Syndrome emerging therapies

• 22q11.2 Deletion Syndrome Market Dynamics: 22q11.2 Deletion Syndrome market drivers and 22q11.2 Deletion Syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• 22q11.2 Deletion Syndrome Unmet Needs, KOL’s views, Analyst’s views, 22q11.2 Deletion Syndrome Market Access and Reimbursement

To know more about 22q11.2 Deletion Syndrome companies working in the treatment market, visit @ 22q11.2 Deletion Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

1. 22q11.2 Deletion Syndrome Market Report Introduction

2. Executive Summary for 22q11.2 Deletion Syndrome

3. SWOT analysis of 22q11.2 Deletion Syndrome

4. 22q11.2 Deletion Syndrome Patient Share (%) Overview at a Glance

5. 22q11.2 Deletion Syndrome Market Overview at a Glance

6. 22q11.2 Deletion Syndrome Disease Background and Overview

7. 22q11.2 Deletion Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of 22q11.2 Deletion Syndrome

9. 22q11.2 Deletion Syndrome Current Treatment and Medical Practices

10. 22q11.2 Deletion Syndrome Unmet Needs

11. 22q11.2 Deletion Syndrome Emerging Therapies

12. 22q11.2 Deletion Syndrome Market Outlook

13. Country-Wise 22q11.2 Deletion Syndrome Market Analysis (2022–2036)

14. 22q11.2 Deletion Syndrome Market Access and Reimbursement of Therapies

15. 22q11.2 Deletion Syndrome Market Drivers

16. 22q11.2 Deletion Syndrome Market Barriers

17. 22q11.2 Deletion Syndrome Appendix

18. 22q11.2 Deletion Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 22q11.2 Deletion Syndrome Market Trends Point to Steady Growth Ahead by 2036, DelveInsight Analysis Reveals | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas, Inc

DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Huntington’s Disease, historical and forecasted epidemiology as well as the Huntington’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Huntington’s Disease Market Report:

https://www.delveinsight.com/report-store/huntingtons-disease-market

Some of the key facts of the Huntington’s Disease Market Report:

• The Huntington’s Disease market size was valued at approximately USD 320 million in 2025 and is expected to expand at a CAGR of 14% during the forecast period from 2026 to 2036.

• In March 2026, uniQure announced that it has received the official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type A meeting held on January 30, 2026, to discuss AMT-130, its investigational gene therapy for Huntington’s disease. The company stated that the FDA indicated the current data are not sufficient to support approval of AMT-130, which comes as disappointing news for the Huntington’s disease community.

• In January 2026, Skyhawk Therapeutics, Inc., a clinical-stage biotech company focused on small-molecule therapies that target RNA, announced encouraging results from a nine-month interim analysis of its investigational Huntington’s disease treatment SKY-0515. The therapy achieved dose-dependent reductions in mutant huntingtin (mHTT) protein, reaching 62% at the 9 mg dose, along with a 26% dose-dependent decrease in PMS1 mRNA—a key contributor to somatic CAG repeat expansion and Huntington’s disease progression. SKY-0515 also showed strong central nervous system exposure and was generally safe and well tolerated in the study.

• In November 2025, The approval prospects for uniQure’s gene therapy candidate for Huntington’s disease are uncertain after the US FDA questioned the sufficiency of the company’s Phase I/II trial data, causing the stock to drop nearly 66% at market open on November 3. The single-use gene therapy, AMT-130, had been positioned to become the first approved treatment for Huntington’s disease following positive mid-stage trial results, which had previously driven uniQure’s stock up 247% in late September. Recent discussions with the FDA indicated that the Phase I/II data would not be adequate for a biologics license application (BLA), a “drastic change” from prior guidance provided in multiple Type B meetings, according to uniQure.

• In October 2025, Celltrion, Inc. announced that the U.S. Food and Drug Administration has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version, adding treatment of hidradenitis suppurativa (HS) in adolescents aged 12 years and older and uveitis (UV) in pediatric patients aged 2 years and above. YUFLYMA was previously approved by the FDA as a biosimilar to Humira® across multiple indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. While HS and uveitis were earlier approved for adult use, this latest decision extends both indications to younger patient populations.

• In September 2025, UniQure reported positive top-line results from its Phase I/II study of AMT-130, a one-time gene therapy for Huntington’s disease (HD). Top-line data provides a rapid summary of key study results at a predetermined timepoint. The update indicates that AMT-130 significantly slows symptom progression and met the trial’s primary endpoint, marking the first time a therapy has demonstrated the ability to alter the course of HD in a clinical setting.

• In June 2025, Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company focused on developing small molecule therapies targeting RNA, announced the dosing of the first patient in its Phase 2/3 FALCON-HD trial. This study is evaluating SKY-0515, an investigational oral RNA splicing modulator for Huntington’s disease. SKY-0515 is designed to lower the production of HTT and PMS1 proteins, both of which play key roles in Huntington’s disease pathology. In a Phase 1 study involving healthy volunteers, SKY-0515 showed a dose-dependent reduction in HTT mRNA, achieving an average 72% decrease at the highest dose, and was generally well tolerated. Additionally, the Phase 1 trial in Huntington’s disease patients, which began in January 2025, completed enrollment ahead of schedule by March 2025.

• In 2025, the total market size of Huntington’s disease by therapies was USD 320 million in the 7MM. The highest revenue was captured by AUSTEDO, accounting for USD 167 million in 2025.

• During the forecast period (2026–2036), pipeline candidates such as SKY-0515, PTC518, and others are expected to drive the growth of the Huntington’s disease market size.

• In the United States, the total number of prevalent cases of Huntington’s disease was 44,000 in 2025, which is expected to increase during the forecast period, i.e., 2026–2036.

• In 2025, the total prevalent cases of Huntington’s disease were 37,000 in EU4 and the UK, which are projected to increase during the forecast period, i.e., 2026–2036.

• Findings from various secondary studies suggest that Huntington’s disease is more prevalent in the elderly population.

• In addition, secondary data suggest that fewer people are identified in stage IV and stage V with Huntington’s disease. In 2025, 80 Stage IV cases of Huntington’s disease and 20 Stage V cases of Huntington’s disease were estimated for Japan.

• In the 7MM, Huntington’s Disease is more prevalent in individuals aged ≥60 years, accounting for approximately 50% of total cases.

• Key Huntington’s Disease Companies: Teva Pharmaceutical, Annexon Biosciences, Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others

• Key Huntington’s Disease Therapies: AUSTEDO (deutetrabenazine/SD-809), ANX005, Pridopidine(ACR-16; Huntexil), Ingrezza (valbenazine), SOM3355(bevantolol), ANX005, VX15/2503 (pepinemab), SAGE-718, AMT-130/ intrastriatal rAAV5-miHTT, RO7234292, Tominersen, Valbenazine, Pepinemab, SRX246, WVE-003, LPM3770164, SOL-175, and others

• The Huntington’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Huntington’s Disease pipeline products will significantly revolutionize the Huntington’s Disease market dynamics.

Huntington’s Disease Overview

Huntington’s disease is a progressive and inherited neurological disorder that affects the brain’s nerve cells, leading to gradual deterioration of cognitive, motor, and psychiatric functions. HD is caused by a mutation in the HTT gene, which produces a protein called huntingtin. The mutation leads to the production of an abnormal form of the huntingtin protein, which accumulates in neurons and disrupts their function.

To Know in detail about the Huntington’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Huntington’s Disease Market Forecast

Huntington’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Huntington’s Disease Epidemiology Segmentation:

The Huntington’s Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Huntington’s Disease

• Prevalent Cases of Huntington’s Disease by severity

• Gender-specific Prevalence of Huntington’s Disease

• Diagnosed Cases of Episodic and Chronic Huntington’s Disease

Download the report to understand which factors are driving Huntington’s Disease epidemiology trends @ Huntington’s Disease Epidemiology Forecast

Huntington’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Huntington’s Disease market or expected to get launched during the study period. The analysis covers Huntington’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Huntington’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Huntington’s Disease Therapies and Key Companies

• Deutetrabenazine (AUSTEDO): Teva Pharmaceuticals

• INGREZZA (valbenazine/NBI-98854): Neurocrine Biosciences

• SKY-0515: Skyhawk Therapeutics

• Votoplam (PTC518): Novartis Pharmaceuticals

• AUSTEDO (deutetrabenazine/SD-809): Teva Pharmaceutical

• ANX005: Annexon Biosciences

• Pridopidine(ACR-16; Huntexil): Prilenia Therapeutics

• Ingrezza (valbenazine): Neurocrine Biosciences

• SOM3355(bevantolol): Som Biotech

• ANX005: Annexon Biosciences

• VX15/2503 (pepinemab): Vaccinex

• SAGE-718: Sage Therapeutics

• AMT-130/ intrastriatal rAAV5-miHTT: UniQure Biopharma

• RO7234292: Roche

• Tominersen: Ionis Pharmaceuticals

• Valbenazine: Neurocrine Biosciences

• Pepinemab: Vaccinex

• SRX246: Azevan Pharmaceuticals

• WVE-003: WaVe life Sciences

• LPM3770164: Luye Pharma Group

• SOL-175: SOLA Biosciences

Discover more about therapies set to grab major Huntington’s Disease market share @ Huntington’s Disease Treatment Market

Huntington’s Disease Market Strengths

• As adult-onset Huntington’s disease is more common than juvenile Huntington’s disease, so with growing geriatricpopulation more elderly patients will be diagnosed with HD knowledge

Huntington’s Disease Market Opportunities

• Huntington’s disease is a rare condition thus, companies developing treatment options for the same can possess several advantages like premium pricing, an Orphan Designation, which comes along with 7 years of market exclusivity in the US, clinical trial subsidies, reduced regulatory fees, and several other benefits.

Scope of the Huntington’s Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Huntington’s Disease Companies: Teva Pharmaceutical, Annexon Biosciences, Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics, UniQure Biopharma, Roche, Ionis Pharmaceuticals, Neurocrine Biosciences, Vaccinex, Azevan Pharmaceuticals, WaVe life Sciences, Luye Pharma Group, SOLA Biosciences, and others

• Key Huntington’s Disease Therapies: AUSTEDO (deutetrabenazine/SD-809), ANX005, Pridopidine(ACR-16; Huntexil), Ingrezza (valbenazine), SOM3355(bevantolol), ANX005, VX15/2503 (pepinemab), SAGE-718, AMT-130/ intrastriatal rAAV5-miHTT, RO7234292, Tominersen, Valbenazine, Pepinemab, SRX246, WVE-003, LPM3770164, SOL-175, and others

• Huntington’s Disease Therapeutic Assessment: Huntington’s Disease current marketed and Huntington’s Disease emerging therapies

• Huntington’s Disease Market Dynamics: Huntington’s Disease market drivers and Huntington’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Huntington’s Disease Unmet Needs, KOL’s views, Analyst’s views, Huntington’s Disease Market Access and Reimbursement

To know more about Huntington’s Disease companies working in the treatment market, visit @ Huntington’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Huntington’s Disease Market Report Introduction

2. Executive Summary for Huntington’s Disease

3. SWOT analysis of Huntington’s Disease

4. Huntington’s Disease Patient Share (%) Overview at a Glance

5. Huntington’s Disease Market Overview at a Glance

6. Huntington’s Disease Disease Background and Overview

7. Huntington’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Huntington’s Disease

9. Huntington’s Disease Current Treatment and Medical Practices

10. Huntington’s Disease Unmet Needs

11. Huntington’s Disease Emerging Therapies

12. Huntington’s Disease Market Outlook

13. Country-Wise Huntington’s Disease Market Analysis (2022–2036)

14. Huntington’s Disease Market Access and Reimbursement of Therapies

15. Huntington’s Disease Market Drivers

16. Huntington’s Disease Market Barriers

17. Huntington’s Disease Appendix

18. Huntington’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Huntington’s Disease Market Expected to Gain Momentum Through 2036, According to DelveInsight | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeu

DelveInsight’s “Mucopolysaccharidosis Type I Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Mucopolysaccharidosis Type I, historical and forecasted epidemiology as well as the Mucopolysaccharidosis Type I market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Mucopolysaccharidosis Type I, offering comprehensive insights into the Mucopolysaccharidosis Type I revenue trends, prevalence, and treatment landscape. The report delves into key Mucopolysaccharidosis Type I statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Mucopolysaccharidosis Type I therapies. Additionally, we cover the landscape of Mucopolysaccharidosis Type I clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Mucopolysaccharidosis Type I treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Mucopolysaccharidosis Type I space.

Get a Free sample for the Mucopolysaccharidosis Type I Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market

Some of the key facts of the Mucopolysaccharidosis Type I Market Report:

• According to DelveInsight’s analysis, the MPS I market size across the 7MM was estimated at nearly USD 155 million in 2025 and is expected to grow at a CAGR of 8.6%, supported by the anticipated launch of advanced therapies and ongoing improvements in clinical management practices.

• In December 2025, anticipating an FDA decision on its Hunter syndrome therapy in April, Denali Therapeutics has secured a $275 million financing agreement with Royalty Pharma to support the potential launch of tividenofusp alfa and further development of its neurodegenerative disease pipeline. This funding follows a three-month delay in tividenofusp alfa’s PDUFA date after Denali submitted updated clinical pharmacology data. The company’s marketing application, based on a Phase I/II study, was granted priority review by the FDA in July 2025. Under the agreement, Royalty Pharma will provide an initial $200 million payment if the therapy receives accelerated FDA approval for Hunter syndrome (MPS II), with an additional $75 million payable upon EMA approval by the end of 2029.

• In June 2025, The European Commission (EC) has awarded orphan drug designation (ODD) to JR-446, an experimental therapy from Medipal and JCR Pharmaceuticals, for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also referred to as Sanfilippo syndrome type B.

• The current standard of care, laronidase (ALDURAZYME), faces limitations in addressing the full systemic and neurological spectrum of the disease. This has fueled the development of innovative candidates like OTL-203, lepunafusp alfa (JR-171), which aim to provide more comprehensive enzyme delivery and improved patient outcomes and reshape the MPS I treatment landscape.

• Among the 7MM, the United States accounted for the largest market size of MPS I, valued at approximately USD 75 million in 2025.

• The EU4 and the UK combined represented a significant market segment, with a total market size of approximately USD 70 million in 2025, driven by steady demand for enzyme replacement therapies.

• Japan accounted for a market size of approximately USD 10 million in 2025, representing the smallest but a growing portion of the total 7MM market.

• The most meaningful recent shift in the treatment landscape has been the focus on addressing the limitations of systemic ERT. While laronidase (ALDURAZYME) remains the standard of care across EU markets, the emergence of next-generation therapies like OTL-203 (Stem cell gene therapy) represents a significant leap. These advanced mechanisms aim to cross the blood-brain barrier and provide more comprehensive disease control, significantly improving the long-term quality of life for patients with severe phenotypes.

• The MPS I pipeline is transitioning toward next-generation gene therapies and recombinant DNA technologies. Assets such as HSC gene therapy (OTL-203) are currently in late-stage (Phase III) clinical development, signaling a major shift toward potentially curative, one-time interventions that could reshape the long-term treatment landscape.

• As of 2025, the diagnosed prevalent population of MPS I across the 7MM is estimated at approximately 650 cases, highlighting both the rarity of the condition and variations in regional diagnostic practices.

• In the year 2025, the United States represents the largest share, with nearly 240 cases, supported by more advanced screening systems and higher disease awareness.

• In 2025, EU4 and the UK together contribute ~400 cases, with the UK representing the largest individual European segment ~110 cases.

• In 2025, Japan accounted for the largest proportion of Scheie syndrome (MPS IS) cases, representing approximately 50% of all MPS I cases based on disease severity.

• In 2025, EU4 and the UK accounted for a significant proportion of Hurler syndrome (MPS IH) cases, with approximately 240 diagnosed cases out of a total cases of MPS I in the region, reflecting the distribution of the disease based on clinical severity.

• Key Mucopolysaccharidosis Type I Companies: BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, and others

• Key Mucopolysaccharidosis Type I Therapies: ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, ISP-001, JWK-008 Chengdu, RGX 111, SIG 005, Pentosan Polysulphate, JNS102, and others

• The Mucopolysaccharidosis Type I market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mucopolysaccharidosis Type I pipeline products will significantly revolutionize the Mucopolysaccharidosis Type I market dynamics.

• DelveInsight estimates that there were approximately 660 diagnosed prevalent cases of Mucopolysaccharidosis I in the 7MM in 2024.

• In 2024, the EU4 and the UK reported the highest number of diagnosed prevalent Mucopolysaccharidosis I cases in the 7MM, representing 60% of the total with around 400 cases.

• In 2024, the United States reported the second-highest number of diagnosed prevalent Mucopolysaccharidosis I cases, with around 240 cases, projected to grow at a CAGR of 0.6% between 2025 and 2036.

• In 2024, the UK had the highest number of diagnosed prevalent Mucopolysaccharidosis I cases among the EU4 and the UK, with about 110 cases. Italy followed with around 75 cases, and Spain reported the lowest, with approximately 60 cases.

• In 2024, Japan had approximately 20 treated cases of MPS I, with this number projected to increase by 2036.

Mucopolysaccharidosis Type I Overview

Mucopolysaccharidosis Type I (MPS I) is a rare genetic disorder caused by a deficiency of the enzyme alpha-L-iduronidase, which is needed to break down certain complex sugars called glycosaminoglycans (GAGs). The accumulation of GAGs in the body leads to progressive damage in multiple organs and tissues, including the heart, liver, spleen, bones, and nervous system. Symptoms can range from skeletal abnormalities, developmental delays, and organ enlargement to respiratory and cardiovascular issues, with severity varying based on the form of the disease (Hurler, Hurler-Scheie, or Scheie).

To Know in detail about the Mucopolysaccharidosis Type I market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mucopolysaccharidosis Type I Market Forecast

Mucopolysaccharidosis Type I Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Mucopolysaccharidosis Type I Epidemiology Segmentation:

The Mucopolysaccharidosis Type I market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Mucopolysaccharidosis Type I

• Prevalent Cases of Mucopolysaccharidosis Type I by severity

• Gender-specific Prevalence of Mucopolysaccharidosis Type I

• Diagnosed Cases of Episodic and Chronic Mucopolysaccharidosis Type I

Download the report to understand which factors are driving Mucopolysaccharidosis Type I epidemiology trends @ Mucopolysaccharidosis Type I Epidemiology Forecast

Mucopolysaccharidosis Type I Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mucopolysaccharidosis Type I market or expected to get launched during the study period. The analysis covers Mucopolysaccharidosis Type I market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mucopolysaccharidosis Type I Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mucopolysaccharidosis Type I Therapies and Key Companies

• ALDURAZYME (laronidase): BioMarin Pharmaceutical/Sanofi

• OTL-203: Orchard Therapeutics/Kyowa Kirin

• Lepunafusp alfa (JR-171): JCR Pharmaceuticals

• RGX-111: REGENXBIO/Nippon Shinyaku

• ISP-001: Immusoft

• JWK-008 Chengdu: Genevector Biotechnology

• Research programme: oligonucleotide based RNA base editing therapeutics EdiGene Inc.

• RGX 111: REGENXBIO

• SIG 005: Sigilon Therapeutics

• Pentosan Polysulphate: Paradigm Biopharma

• JNS102: Jupiter Neurosciences

Discover more about therapies set to grab major Mucopolysaccharidosis Type I market share @ Mucopolysaccharidosis Type I Treatment Landscape

Mucopolysaccharidosis Type I Market Drivers

• Rising Prevalence of MPS I: Increasing awareness and diagnosis of MPS I are driving demand for effective therapies.

• Advancements in Enzyme Replacement Therapies (ERTs): Development of therapies like ALDURAZYME and emerging candidates (OTL-203, JR-171, RGX-111) is expanding treatment options.

• Supportive Regulatory Environment: Orphan drug designations and fast-track approvals are encouraging innovation in MPS I therapeutics.

• Growing Patient Awareness & Screening Programs: Improved early diagnosis through genetic testing and newborn screening is boosting market potential.

Mucopolysaccharidosis Type I Market Barriers

• High Treatment Costs: ERTs and gene therapies for MPS I are expensive, limiting accessibility in some regions.

• Limited Awareness in Certain Regions: Lack of diagnosis and awareness in emerging markets hampers patient identification.

• Safety & Long-Term Efficacy Concerns: Potential adverse effects and uncertainties about long-term benefits of novel therapies may restrict adoption.

• Small Patient Population: The rarity of MPS I limits the overall market size compared to more prevalent diseases.

Scope of the Mucopolysaccharidosis Type I Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Mucopolysaccharidosis Type I Companies: BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, and others

• Key Mucopolysaccharidosis Type I Therapies: ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, ISP-001, JWK-008 Chengdu, RGX 111, SIG 005, Pentosan Polysulphate, JNS102, and others

• Mucopolysaccharidosis Type I Therapeutic Assessment: Mucopolysaccharidosis Type I current marketed and Mucopolysaccharidosis Type I emerging therapies

• Mucopolysaccharidosis Type I Market Dynamics: Mucopolysaccharidosis Type I market drivers and Mucopolysaccharidosis Type I market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Mucopolysaccharidosis Type I Unmet Needs, KOL’s views, Analyst’s views, Mucopolysaccharidosis Type I Market Access and Reimbursement

To know more about Mucopolysaccharidosis Type I companies working in the treatment market, visit @ Mucopolysaccharidosis Type I Clinical Trials and Therapeutic Assessment

Table of Contents

1. Mucopolysaccharidosis Type I Market Report Introduction

2. Executive Summary for Mucopolysaccharidosis Type I

3. SWOT analysis of Mucopolysaccharidosis Type I

4. Mucopolysaccharidosis Type I Patient Share (%) Overview at a Glance

5. Mucopolysaccharidosis Type I Market Overview at a Glance

6. Mucopolysaccharidosis Type I Disease Background and Overview

7. Mucopolysaccharidosis Type I Epidemiology and Patient Population

8. Country-Specific Patient Population of Mucopolysaccharidosis Type I

9. Mucopolysaccharidosis Type I Current Treatment and Medical Practices

10. Mucopolysaccharidosis Type I Unmet Needs

11. Mucopolysaccharidosis Type I Emerging Therapies

12. Mucopolysaccharidosis Type I Market Outlook

13. Country-Wise Mucopolysaccharidosis Type I Market Analysis (2022–2036)

14. Mucopolysaccharidosis Type I Market Access and Reimbursement of Therapies

15. Mucopolysaccharidosis Type I Market Drivers

16. Mucopolysaccharidosis Type I Market Barriers

17. Mucopolysaccharidosis Type I Appendix

18. Mucopolysaccharidosis Type I Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mucopolysaccharidosis Type I Market Growth to Surge During Forecast Period (2026–2036), Says DelveInsight | BioMarin Pharma, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharma, Nippon Shinyaku

DelveInsight’s “Head and Neck Squamous Cell Carcinomas Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Head and Neck Squamous Cell Carcinomas, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinomas market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Head and Neck Squamous Cell Carcinomas Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market

Some of the key facts of the Head and Neck Squamous Cell Carcinomas Market Report:

• The HNSCC market size was valued at approximately USD 850 million in 2025 and is anticipated to reach nearly USD 2.56 billion by 2036, registering a CAGR of 10.5% throughout the forecast period from 2026 to 2036.

• In May 2026, A study evaluating ficerafusp alfa in combination with Keytruda (pembrolizumab) as a loading dose followed by maintenance dosing every three weeks in first-line recurrent/metastatic HPV-negative HNSCC is anticipated to begin in Q3 2026. Additionally, long-term follow-up findings from the Phase 1b trial assessing the combination in 1L R/M HPV-negative HNSCC patients are scheduled for presentation at ASCO Annual Meeting 2026.

• In February 2026, The FDA has granted breakthrough therapy designation (BTD) to amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO; subcutaneous amivantamab) as monotherapy for the treatment of adult patients with recurrent or metastatic, HPV–unrelated HNSCC following disease progression on or after platinum-based chemotherapy and a PD-L1 or PD-1 inhibitor.

• In August 2025, Merus announced that enrollment in the Phase III LiGeR-HN2 trial in HNSCC is expected to be completed by the end of 2025, and in May 2025, the company further announced that it anticipates sharing a topline interim readout in 2026 for Petosemtamab (MCLA-158).

• In August 2025, Health Canada has authorized pembrolizumab (Keytruda) for use as neoadjuvant therapy, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and then as monotherapy, for adult patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors show a PD-L1 combined positive score (CPS) of 1 or higher, as confirmed by a validated test.

• In February 2025, Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for solid tumors, has announced the enrollment of the first patients in FORTIFI-HN01, a pivotal Phase 2/3 trial. This study evaluates ficerafusp alfa in combination with pembrolizumab as a first-line (1L) treatment for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).

• In January 2025, Rakuten Medical administered the first dose in its intercontinental Phase III clinical trial evaluating ASP-1929, a photoimmunotherapy treatment for recurrent head and neck squamous cell carcinoma (HNSCC). This multi-center, randomized, open-label study will assess the efficacy of the company’s antibody-dye conjugate, which combines the antibody drug cetuximab with MSD’s leading monoclonal antibody, Keytruda (pembrolizumab).

• KEYTRUDA and OPDIVO are the primary PD-1 inhibitors approved for treating recurrent or metastatic (R/M) HNSCC.

• KEYTRUDA monotherapy is the preferred first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression. However, only about 20% of patients respond, and there is no significant difference based on HPV status. Currently, no treatments are specifically approved for HPV16+ cancers.

• According to DelveInsight’s estimates, the total incident cases of HNSCC in the 7MM were approximately 153,500 in 2025.

• It has been observed that among EU4 and the UK, site-specific cases of HNSCC were found maximum in the oral cavity in 2025.

• Germany accounted for about 2,700 Oropharyngeal squamous cell cancer (OPSCC) incident cases in 2025.

• Japan accounted for about 3,900 cases of HPV16+ OPSCC incident cases in 2025.

• Key Head and Neck Squamous Cell Carcinomas Companies: M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals, Hansoh BioMedical R&D Company, Gilead Sciences, Merck Sharp & Dohme LLC, Exelixis, Sichuan Baili Pharmaceutical Co., Ltd., AVEO Pharmaceuticals, Inc., Benitec Biopharma, Inc., BeiGene, ALX Oncology Inc., Queensland Health, Regeneron Pharmaceuticals, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• The Head and Neck Squamous Cell Carcinomas market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Head and Neck Squamous Cell Carcinomas pipeline products will significantly revolutionize the Head and Neck Squamous Cell Carcinomas market dynamics.

Head and Neck Squamous Cell Carcinomas Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) refers to a group of cancers that originate in the squamous cells lining the mucous membranes of the head and neck region. This includes the oral cavity, throat (pharynx), and voice box (larynx), among other areas. Squamous cells are flat, thin cells that make up the epithelium, the outer layer of the skin and the lining of various organs.

To Know in detail about the Head and Neck Squamous Cell Carcinomas market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Head and Neck Squamous Cell Carcinomas Market Forecast

Head and Neck Squamous Cell Carcinomas Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2022-2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Head and Neck Squamous Cell Carcinomas Epidemiology Segmentation:

The Head and Neck Squamous Cell Carcinomas market report proffers epidemiological analysis for the study period 2022-2036 in the APAC region is segmented into:

• Total Prevalence of Head and Neck Squamous Cell Carcinomas

• Prevalent Cases of Head and Neck Squamous Cell Carcinomas by severity

• Gender-specific Prevalence of Head and Neck Squamous Cell Carcinomas

• Diagnosed Cases of Episodic and Chronic Head and Neck Squamous Cell Carcinomas

Download the report to understand which factors are driving Head and Neck Squamous Cell Carcinomas epidemiology trends @ Head and Neck Squamous Cell Carcinomas Epidemiology Forecast

Head and Neck Squamous Cell Carcinomas Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Squamous Cell Carcinomas market or expected to get launched during the study period. The analysis covers Head and Neck Squamous Cell Carcinomas market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Head and Neck Squamous Cell Carcinomas Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Head and Neck Squamous Cell Carcinomas Therapies and Key Companies

• (KEYTRUDA): Merck Sharp & Dohme

• Efti (eftilagimod alfa): Immutep/ Merck

• Pembrolizumab: M.D. Anderson Cancer Center

• Nivolumab: Sidney Kimmel

• Durvalumab: Centre hospitalier de

• Taxotere: Dana-Farber Cancer Institute

• CELLECTRA™-5P: Inovio Pharmaceuticals

• HS-20093: Hansoh BioMedical R&D Company

• Magrolimab: Gilead Sciences

• Lenvatinib: Merck Sharp & Dohme LLC

• Zanzalintinib: Exelixis

• BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

• Ficlatuzumab: AVEO Pharmaceuticals, Inc.

• BB-401: Benitec Biopharma, Inc.

• Tislelizumab: BeiGene

• SI-B001: Sichuan Baili Pharmaceutical Co., Ltd.

• Evorpacept: ALX Oncology Inc.

• Pembrolizumab: Queensland Health

• Evorpacept: ALX Oncology Inc.

• CMP-001: Regeneron Pharmaceuticals

Discover more about therapies set to grab major Head and Neck Squamous Cell Carcinomas market share @ Head and Neck Squamous Cell Carcinomas Treatment Landscape

Head and Neck Squamous Cell Carcinomas Market Drivers

• Rising incidence of tobacco use, alcohol consumption, and human papillomavirus (HPV)-associated cancers is significantly driving the prevalence of head and neck squamous cell carcinomas (HNSCC).

• Increasing awareness regarding early cancer diagnosis and growing adoption of advanced screening technologies are supporting timely treatment initiation.

• Advancements in immunotherapy, targeted therapy, and precision oncology are expanding treatment options and improving patient outcomes.

• Growing clinical trial activity focused on checkpoint inhibitors, monoclonal antibodies, and combination therapies is strengthening the HNSCC treatment pipeline.

Head and Neck Squamous Cell Carcinomas Market Barriers

• Late-stage diagnosis in many patients due to non-specific symptoms can limit treatment effectiveness and survival rates.

• High treatment costs associated with immunotherapies, biologics, and advanced radiation procedures may restrict accessibility in developing regions.

• Severe treatment-related side effects such as dysphagia, mucositis, and speech impairment may negatively impact patient quality of life and treatment adherence.

• Resistance to chemotherapy and immunotherapy in certain patient populations remains a major clinical challenge.

Scope of the Head and Neck Squamous Cell Carcinomas Market Report

• Study Period: 2022-2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Head and Neck Squamous Cell Carcinomas Companies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Head and Neck Squamous Cell Carcinomas Therapeutic Assessment: Head and Neck Squamous Cell Carcinomas current marketed and Head and Neck Squamous Cell Carcinomas emerging therapies

• Head and Neck Squamous Cell Carcinomas Market Dynamics: Head and Neck Squamous Cell Carcinomas market drivers and Head and Neck Squamous Cell Carcinomas market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Head and Neck Squamous Cell Carcinomas Unmet Needs, KOL’s views, Analyst’s views, Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement

To know more about Head and Neck Squamous Cell Carcinomas companies working in the treatment market, visit @ Head and Neck Squamous Cell Carcinomas Clinical Trials and Therapeutic Assessment

Table of Contents

1. Head and Neck Squamous Cell Carcinomas Market Report Introduction

2. Executive Summary for Head and Neck Squamous Cell Carcinomas

3. SWOT analysis of Head and Neck Squamous Cell Carcinomas

4. Head and Neck Squamous Cell Carcinomas Patient Share (%) Overview at a Glance

5. Head and Neck Squamous Cell Carcinomas Market Overview at a Glance

6. Head and Neck Squamous Cell Carcinomas Disease Background and Overview

7. Head and Neck Squamous Cell Carcinomas Epidemiology and Patient Population

8. Country-Specific Patient Population of Head and Neck Squamous Cell Carcinomas

9. Head and Neck Squamous Cell Carcinomas Current Treatment and Medical Practices

10. Head and Neck Squamous Cell Carcinomas Unmet Needs

11. Head and Neck Squamous Cell Carcinomas Emerging Therapies

12. Head and Neck Squamous Cell Carcinomas Market Outlook

13. Country-Wise Head and Neck Squamous Cell Carcinomas Market Analysis (2022-2036)

14. Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement of Therapies

15. Head and Neck Squamous Cell Carcinomas Market Drivers

16. Head and Neck Squamous Cell Carcinomas Market Barriers

17. Head and Neck Squamous Cell Carcinomas Appendix

18. Head and Neck Squamous Cell Carcinomas Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck Squamous Cell Carcinomas Market Set for Robust Expansion Through 2036, DelveInsight Reports | Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals

DelveInsight’s “Gene and Cell Therapies Targeting CNS Disorders Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Gene and Cell Therapies Targeting CNS Disorders, historical and forecasted epidemiology as well as the Gene and Cell Therapies Targeting CNS Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Gene and Cell Therapies Targeting CNS Disorders Market Report:

https://www.delveinsight.com/report-store/gene-and-cell-therapies-targeting-cns-disorders-market

Some of the key facts of the Gene and Cell Therapies Targeting CNS Disorders Market Report:

• The Gene and Cell Therapies Targeting CNS Disorders market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

• In March 2026, Denali Therapeutics announced the US Food and Drug Administration (FDA) had granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain, for the treatment of neurologic manifestations of Hunter syndrome.

• In March 2026, uniQure announced that the company received final meeting minutes from the US FDA regarding a Type A meeting held on January 30, 2026, to discuss AMT-130, an investigational gene therapy for Huntington’s disease. uniQure intends to continue engaging with the FDA regarding Phase III development considerations and plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.

• In December 2025, AskBio announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) had granted the Pioneering Regenerative Medical Product designation (SAKIGAKE) for two of AskBio’s investigational gene therapy programs: AB-1005, for the treatment of Parkinson’s disease.

• In December 2025, Bayer and its wholly owned, independently operated subsidiary BlueRock Therapeutics announced that the investigative cell therapy bemdaneprocel had received Pioneering Regenerative Medical Product designation (SAKIGAKE) from Japan’s MHLW.

• In August 2025, the FDA approved new safety labeling changes for SKYSONA due to the increased risk of hematologic malignancy.

• According to DelveInsight analysis, in 2025, there were 1,290,000 diagnosed prevalent cases of Parkinson’s disease in the US, and the cases are expected to increase at a CAGR of ~3%.

• In 2025, the number of Amyotrophic Lateral Sclerosis (ALS) cases in the United States was ~30,000.

• In the United States, the total number of diagnosed prevalent cases of Huntington’s disease was 25,000 in 2025, which is expected to increase during the forecast period, i.e., 2026–2036.

• In 2025, the total number of diagnosed prevalent cases of Alzheimer’s disease in the 7MM was 17,000,000. Among the 7MM countries, the US accounted for the highest number of diagnosed prevalent cases of Alzheimer’s disease, contributing around 45%, while the UK reported the lowest number of cases in 2025.

• Key Gene and Cell Therapies Targeting CNS Disorders Companies: In8bio Inc., Brainstorm Cell Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Atara Biotherapeutics, Neuroplast, UniQure Biopharma, Asklepios Biopharmaceutical, Inc., Brain Neurotherapy Bio, Inc., Myrtelle Inc., Forge Biologics, Inc, Sio Gene Therapies, Lexeo Therapeutics, Partner Therapeutics, Inc., Hoffmann-La Roche, Novartis, Freeline Therapeutics, Passage Bio, Inc., Black Diamond Therapeutics, Inc., and others

• Key Gene and Cell Therapies Targeting CNS Disorders Therapies: DRI cell therapy, NurOwn, VY-AADC02, ATA188, Neuro-Cells, AMT-130, AAV2-GDNF, rAAV-Olig001-ASPA, FBX-101, AAV9-GLB1, LX2006, Sargramostim, Entrectinib, ACTUS-101, Capmatinib, FLT201, PBKR03, BDTX-4933, and others

• The Gene and Cell Therapies Targeting CNS Disorders market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gene and Cell Therapies Targeting CNS Disorders pipeline products will significantly revolutionize the Gene and Cell Therapies Targeting CNS Disorders market dynamics.

Gene and Cell Therapies Targeting CNS Disorders Overview

Gene and cell therapies targeting CNS (Central Nervous System) disorders represent advanced treatment approaches aimed at addressing diseases that affect the brain and spinal cord. These therapies leverage genetic engineering and cellular techniques to modify or replace malfunctioning cells and genes, aiming to restore normal function or halt disease progression.

To Know in detail about the Gene and Cell Therapies Targeting CNS Disorders market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gene and Cell Therapies Targeting CNS Disorders Market Forecast

Gene and Cell Therapies Targeting CNS Disorders Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gene and Cell Therapies Targeting CNS Disorders Epidemiology Segmentation:

The Gene and Cell Therapies Targeting CNS Disorders market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Gene and Cell Therapies Targeting CNS Disorders

• Prevalent Cases of Gene and Cell Therapies Targeting CNS Disorders by severity

• Gender-specific Prevalence of Gene and Cell Therapies Targeting CNS Disorders

• Diagnosed Cases of Episodic and Chronic Gene and Cell Therapies Targeting CNS Disorders

Download the report to understand which factors are driving Gene and Cell Therapies Targeting CNS Disorders epidemiology trends @ Gene and Cell Therapies Targeting CNS Disorders Epidemiology Forecast

Gene and Cell Therapies Targeting CNS Disorders Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gene and Cell Therapies Targeting CNS Disorders market or expected to get launched during the study period. The analysis covers Gene and Cell Therapies Targeting CNS Disorders market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gene and Cell Therapies Targeting CNS Disorders Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gene and Cell Therapies Targeting CNS Disorders Therapies and Key Companies

• Tividenofusp alfa-eknm (AVLAYAH): Denali Therapeutics

• Atidarsagene autotemcel (LENMELDY/ LIBMELDY): Kyowa Kirin

• Eladocagene exuparvovec-tneq (KEBILIDI/ UPSTAZA): PTC Therapeutics

• Elivaldogene autotemcel (SKYSONA): Genetix Biotherapeutics

• Bemdaneprocel (BRT-DA01): BlueRock Therapeutics (Bayer subsidiary)

• AB-1005: Bayer and AskBio

• DRI cell therapy: In8bio Inc.

• NurOwn: Brainstorm Cell Therapeutics

• VY-AADC02: Neurocrine Biosciences/Voyager Therapeutics

• ATA188: Atara Biotherapeutics

• Neuro-Cells: Neuroplast

• AMT-130: UniQure Biopharma

• AAV2-GDNF: Asklepios Biopharmaceutical, Inc./Brain Neurotherapy Bio, Inc.

• rAAV-Olig001-ASPA: Myrtelle Inc.

• FBX-101: Forge Biologics, Inc

• AAV9-GLB1: Sio Gene Therapies

• LX2006: Lexeo Therapeutics

• Sargramostim: Partner Therapeutics, Inc.

• Entrectinib: Hoffmann-La Roche

• ACTUS-101: Asklepios Biopharmaceutical, Inc.

• Capmatinib: Novartis

• FLT201: Freeline Therapeutics

• PBKR03: Passage Bio, Inc.

• BDTX-4933: Black Diamond Therapeutics, Inc.

Discover more about therapies set to grab major Gene and Cell Therapies Targeting CNS Disorders market share @ Gene and Cell Therapies Targeting CNS Disorders Treatment Market

Gene and Cell Therapies Targeting CNS Disorders Market Drivers

• Rising prevalence of neurological and neurodegenerative disorders such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS) is driving demand for advanced therapeutic solutions.

• Growing advancements in gene editing technologies, viral vectors, and stem cell therapies are accelerating innovation in CNS-targeted treatments.

• Increasing investments from biotechnology companies, pharmaceutical firms, and government organizations are supporting research and clinical development activities.

• Strong progress in precision medicine and personalized therapeutics is improving the development of targeted treatments for rare and genetic CNS disorders.

Gene and Cell Therapies Targeting CNS Disorders Market Barriers

• High development and manufacturing costs associated with gene and cell therapies remain a significant market challenge.

• Complexities related to safe and effective delivery across the blood-brain barrier may limit therapeutic success.

• Limited long-term safety and efficacy data for emerging therapies can create regulatory and commercialization hurdles.

• Risk of immune reactions, off-target effects, and neurological complications may impact patient safety and clinical adoption.

Scope of the Gene and Cell Therapies Targeting CNS Disorders Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Gene and Cell Therapies Targeting CNS Disorders Companies: In8bio Inc., Brainstorm Cell Therapeutics, Neurocrine Biosciences, Voyager Therapeutics, Atara Biotherapeutics, Neuroplast, UniQure Biopharma, Asklepios Biopharmaceutical, Inc., Brain Neurotherapy Bio, Inc., Myrtelle Inc., Forge Biologics, Inc, Sio Gene Therapies, Lexeo Therapeutics, Partner Therapeutics, Inc., Hoffmann-La Roche, Novartis, Freeline Therapeutics, Passage Bio, Inc., Black Diamond Therapeutics, Inc., and others

• Key Gene and Cell Therapies Targeting CNS Disorders Therapies: DRI cell therapy, NurOwn, VY-AADC02, ATA188, Neuro-Cells, AMT-130, AAV2-GDNF, rAAV-Olig001-ASPA, FBX-101, AAV9-GLB1, LX2006, Sargramostim, Entrectinib, ACTUS-101, Capmatinib, FLT201, PBKR03, BDTX-4933, and others

• Gene and Cell Therapies Targeting CNS Disorders Therapeutic Assessment: Gene and Cell Therapies Targeting CNS Disorders current marketed and Gene and Cell Therapies Targeting CNS Disorders emerging therapies

• Gene and Cell Therapies Targeting CNS Disorders Market Dynamics: Gene and Cell Therapies Targeting CNS Disorders market drivers and Gene and Cell Therapies Targeting CNS Disorders market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Gene and Cell Therapies Targeting CNS Disorders Unmet Needs, KOL’s views, Analyst’s views, Gene and Cell Therapies Targeting CNS Disorders Market Access and Reimbursement

To know more about Gene and Cell Therapies Targeting CNS Disorders companies working in the treatment market, visit @ Gene and Cell Therapies Targeting CNS Disorders Treatment Landscape

Table of Contents

1. Gene and Cell Therapies Targeting CNS Disorders Market Report Introduction

2. Executive Summary for Gene and Cell Therapies Targeting CNS Disorders

3. SWOT analysis of Gene and Cell Therapies Targeting CNS Disorders

4. Gene and Cell Therapies Targeting CNS Disorders Patient Share (%) Overview at a Glance

5. Gene and Cell Therapies Targeting CNS Disorders Market Overview at a Glance

6. Gene and Cell Therapies Targeting CNS Disorders Disease Background and Overview

7. Gene and Cell Therapies Targeting CNS Disorders Epidemiology and Patient Population

8. Country-Specific Patient Population of Gene and Cell Therapies Targeting CNS Disorders

9. Gene and Cell Therapies Targeting CNS Disorders Current Treatment and Medical Practices

10. Gene and Cell Therapies Targeting CNS Disorders Unmet Needs

11. Gene and Cell Therapies Targeting CNS Disorders Emerging Therapies

12. Gene and Cell Therapies Targeting CNS Disorders Market Outlook

13. Country-Wise Gene and Cell Therapies Targeting CNS Disorders Market Analysis (2022–2036)

14. Gene and Cell Therapies Targeting CNS Disorders Market Access and Reimbursement of Therapies

15. Gene and Cell Therapies Targeting CNS Disorders Market Drivers

16. Gene and Cell Therapies Targeting CNS Disorders Market Barriers

17. Gene and Cell Therapies Targeting CNS Disorders Appendix

18. Gene and Cell Therapies Targeting CNS Disorders Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gene and Cell Therapies Targeting CNS Disorders Market to Witness Promising Upswing by 2036, DelveInsight Forecasts | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Therapeutics, NeurocrineBioscience